Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1317 clinical trials
HER2-PREDICT: Translational Study of Tumor Samples From DS8201-A-U301 and DS8201-A-U302 Trials.

Patients who will participate, are participating or have participated in Daichi Sankyo INC sponsored Ds8201-A-U301 and Ds8201-A-U302 trials will be asked to participate to HER2-PREDICT study offering them a new informed consent. In order to identify mRNA ERBB2 levels, we will evaluate by gene expression tumor samples from these patients.

bone metastases
epidermal growth factor receptor
cancer
HER2
primary tumor
  • 0 views
  • 19 Feb, 2024
A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome

Approximately 20 patients (male and female) 4 and 17 years of age with a genetically confirmed diagnosis of full maternal UBE3A gene deletion (within 15q11.2-q13 region) will be enrolled.

  • 0 views
  • 19 Feb, 2024
A Study of DCC-2618 (Ripretinib) Evaluating Efficacy Safety and Pharmacokinetics In Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

The primary objective of this trial is to evaluate the progress free survival (PFS) of DCC-2618 in patients with advanced gastrointestinal stromal tumors who have progressed with prior anticancer therapies based on independent radiologic review.This study will enroll approximately 35 subjects in up to 10 sites in China mainland, and …

dcc-2618
gastrointestinal stromal tumor
stromal tumor
measurable disease
ripretinib
  • 0 views
  • 19 Feb, 2024
Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy

The purpose of this additional part of the study is to test whether the study drug, nivolumab, is a safe treatment that will prevent participants' primary central nervous system lymphoma (PCNSL) from growing again (recurrence). Participants will be people with PCNSL who continue to have cell free tumor DNA (cfDNA) …

neutrophil count
ffpe
serum bilirubin level
lymphoma
platelet transfusion
  • 0 views
  • 19 Feb, 2024
Phase 2 Trial in Multiple Brain Metastases Outcomes With HA-SIB-WBRT

Patients who are fit, have multiple brain metastases (5-25 lesions) and reasonable life expectancy (>6 months) will be recruited from NCCS over 2 years. Patients will be followed up the over the following year with imaging, toxicity data, quality of life, activities of daily living and cognitive measurements at set …

brain metastasis
serum pregnancy test
treatment regimen
cancer
edema
  • 0 views
  • 19 Feb, 2024
UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy

Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with [C-11]PiB-PET, and cognitive status will be the primary outcome of this imaging study.

amyloid
amyloidosis
alzheimer's disease
  • 0 views
  • 19 Feb, 2024
  • 1 location
Effects of Pau d' Arco in Primary Dysmenorrhea

A single arm, open-label trial evaluating safety and tolerability of encapsulated Tabebuia avellanedae in 12 generally healthy women aged 18-45 with primary dysmenorrhea (PDM). This will be the first study evaluating the safety and tolerability of Tabebuia avellanedae in PDM. We also aim to collect proof-of-concept mechanistic data supporting the …

paragard
copper
fasting
dysmenorrhea
  • 0 views
  • 19 Feb, 2024
FemBloc Permanent Contraception Trial

The purpose of this study is to evaluate if changes to the FemBloc Permanent Contraceptive System are effective in increasing reliance (the ability of a woman to be able to depend on FemBloc for contraception once the treatment and confirmation test have been performed), and decreasing pregnancy rate.

  • 0 views
  • 19 Feb, 2024
Part II: Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia

., patients who did not undergo Kasai surgery). Subjects who participate in the trial will be followed for 2 years.

cholangiography
cholestasis
gcsf
granulocyte colony stimulating factor
colony stimulating factor
  • 0 views
  • 19 Feb, 2024
Evaluation of a New Supporting Ostomy Product

It is the expectation that median wear time is slightly reduced in the period when subjects are using the supporting product with their ostomy appliance. Long-term benefits of the test product may be less skin redness, less worry of leakage and/or improvement in quality of life and social activities.

  • 0 views
  • 19 Feb, 2024